Ola Nilsson

Company: NEOGAP Therapeutics

Job title: Head Of Neoantigen Production, Development & Clinical Processing

Seminars:

A First-in-Human Phase I/IIa Trial of Personalised Tumour-Trained Lymphocytes (pTTL) Derived From Regional Lymph Nodes for the Treatment of Colorectal Cancer 11:30 am

Examining pTTL (personalised Tumour-Trained Lymphocytes), a novel adoptive T-cell therapy product targeting tumour neoantigens. It is applicable to any cancer type for which neoantigens can be identified Understanding how therapy is personalised, tailored for the patient’s own tumour and consists of autologuous neoantigen selected T-cells derived from regional lymph nodes (RLN) Unveiling a first-in-human trial…Read more

day: Day Two